S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
Critical asset just had biggest fall on record (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
Critical asset just had biggest fall on record (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
Critical asset just had biggest fall on record (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
Critical asset just had biggest fall on record (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
NASDAQ:CLDX

Celldex Therapeutics (CLDX) Stock Price, News & Analysis

$48.23
+10.48 (+27.76%)
(As of 02/26/2024 ET)
Today's Range
$38.96
$48.94
50-Day Range
$35.22
$48.23
52-Week Range
$22.11
$48.96
Volume
4.82 million shs
Average Volume
797,452 shs
Market Capitalization
$2.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.00

Celldex Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
9.9% Upside
$53.00 Price Target
Short Interest
Bearish
14.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.32mentions of Celldex Therapeutics in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.84) to ($3.31) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.10 out of 5 stars

Medical Sector

898th out of 942 stocks

Diagnostic Substances Industry

12th out of 13 stocks


CLDX stock logo

About Celldex Therapeutics Stock (NASDAQ:CLDX)

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. It has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

CLDX Stock Price History

CLDX Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Celldex Therapeutics: Q4 Earnings Insights
Celldex: Q4 Earnings Snapshot
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
CLDX Mar 2024 60.000 call
MoneyShow's Best Investment Ideas For 2024: Part 3
What 7 Analyst Ratings Have To Say About Celldex Therapeutics
See More Headlines
Receive CLDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
2/26/2024
Next Earnings (Estimated)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CLDX
CUSIP
15117B10
Employees
148
Year Founded
1983

Price Target and Rating

Average Stock Price Target
$53.00
High Stock Price Target
$80.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+9.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-112,320,000.00
Net Margins
-2,854.75%
Pretax Margin
-2,854.75%

Debt

Sales & Book Value

Annual Sales
$2.36 million
Book Value
$6.93 per share

Miscellaneous

Free Float
45,515,000
Market Cap
$2.28 billion
Optionable
Optionable
Beta
1.41

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives















CLDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Celldex Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CLDX shares.
View CLDX analyst ratings
or view top-rated stocks.

What is Celldex Therapeutics' stock price target for 2024?

4 Wall Street research analysts have issued 1 year price objectives for Celldex Therapeutics' shares. Their CLDX share price targets range from $27.00 to $80.00. On average, they expect the company's share price to reach $53.00 in the next year. This suggests a possible upside of 9.9% from the stock's current price.
View analysts price targets for CLDX
or view top-rated stocks among Wall Street analysts.

How have CLDX shares performed in 2024?

Celldex Therapeutics' stock was trading at $39.66 on January 1st, 2024. Since then, CLDX stock has increased by 21.6% and is now trading at $48.23.
View the best growth stocks for 2024 here
.

Are investors shorting Celldex Therapeutics?

Celldex Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 6,710,000 shares, an increase of 7.9% from the January 15th total of 6,220,000 shares. Based on an average trading volume of 787,700 shares, the days-to-cover ratio is currently 8.5 days.
View Celldex Therapeutics' Short Interest
.

When is Celldex Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our CLDX earnings forecast
.

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) released its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.09. The biopharmaceutical company earned $0.15 million during the quarter, compared to analyst estimates of $1.70 million. Celldex Therapeutics had a negative trailing twelve-month return on equity of 43.22% and a negative net margin of 2,854.75%.

What ETFs hold Celldex Therapeutics' stock?

ETFs with the largest weight of Celldex Therapeutics (NASDAQ:CLDX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO).SPDR S&P Biotech ETF (XBI).

When did Celldex Therapeutics' stock split?

Shares of Celldex Therapeutics reverse split on the morning of Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Celldex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX).

Who are Celldex Therapeutics' major shareholders?

Celldex Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Eventide Asset Management LLC (7.68%), Vanguard Group Inc. (6.45%), Kynam Capital Management LP (6.36%), Point72 Asset Management L.P. (5.83%), Bellevue Group AG (5.11%) and Octagon Capital Advisors LP (1.50%). Insiders that own company stock include Diane C Young, Elizabeth Crowley, Freddy A Jimenez, Samuel Bates Martin and Sarah Cavanaugh.
View institutional ownership trends
.

How do I buy shares of Celldex Therapeutics?

Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLDX) was last updated on 2/27/2024 by MarketBeat.com Staff